Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Fabiola Atzeni, Antonio Carriero, Laura Boccassini & Salvatore D’Angelo. (2021) Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. ImmunoTargets and Therapy 10, pages 141-153.
Read now
Read now
Timo Purmonen, Kari Puolakka, Dinesh Mishra, Praveen Gunda & Janne Martikainen. (2019) Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland. ClinicoEconomics and Outcomes Research 11, pages 159-168.
Read now
Read now
Daniel Wendling, Frank Verhoeven & Clément Prati. (2019) Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy 19:1, pages 55-64.
Read now
Read now
Ron Goeree, Sima Chiva-Razavi, Praveen Gunda, Minal Jain & Steffen M. Jugl. (2019) Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. Journal of Medical Economics 22:1, pages 45-52.
Read now
Read now
Gaëlle Clavel, Marie-Christophe Boissier, Johanna Sigaux & Luca Semerano. (2017) Developments with experimental and investigational drugs for axial spondyloarthritis. Expert Opinion on Investigational Drugs 26:7, pages 833-842.
Read now
Read now
Eric Toussirot. (2017) New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents. Expert Opinion on Pharmacotherapy 18:3, pages 275-282.
Read now
Read now
Articles from other publishers (14)
Fausto Salaffi, Cesare Siragusano, Alessandra Alciati, Giulia Cassone, Salvatore D’Angelo, Serena Guiducci, Ennio Giulio Favalli, Fabrizio Conti, Elisa Gremese, Florenzo Iannone, Roberto Caporali, Marco Sebastiani, Gian Franco Ferraccioli, Giovanni Lapadula & Fabiola Atzeni. (2022) Axial Spondyloarthritis: Reshape the Future—From the “2022 GISEA International Symposium”. Journal of Clinical Medicine 11:24, pages 7537.
Crossref
Crossref
Berkan Armağan, Levent Kılıç, Bayram Farisoğulları, Gözde Kübra Yardımcı, Emre Bilgin, Ertuğrul Çağrı Bölek, Ömer Karadağ, Şule Apraş Bilgen, Sedat Kiraz, İhsan Ertenli & Umut Kalyoncu. (2022) Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis. Rheumatology International 43:1, pages 147-156.
Crossref
Crossref
Kyunghwan Cho & Austin Kang. (2022) Home-based rehabilitation in patients over 60 with stabilized ankylosing spondylitis during the COVID-19 pandemic. Journal of Back and Musculoskeletal Rehabilitation 35:2, pages 261-269.
Crossref
Crossref
Xenofon Baraliakos, Filip Van den Bosch, Pedro M. Machado, Lianne S. Gensler, Helena Marzo-Ortega, Bintu Sherif, Erhard Quebe-Fehling, Brian Porter, Corine Gaillez & Atul Deodhar. (2020) Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies. Rheumatology and Therapy 8:1, pages 273-288.
Crossref
Crossref
Jürgen Braun, Uta Kiltz, Björn Bühring & Xenofon Baraliakos. (2021) Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence. Therapeutic Advances in Musculoskeletal Disease 13, pages 1759720X2110418.
Crossref
Crossref
Ge Yang & Yuanyu Huang. 2021. Aptamers for Medical Applications. Aptamers for Medical Applications
129
178
.
Jordi Gratacós, Petra Díaz del Campo Fontecha, Cristina Fernández-Carballido, Xavier Juanola Roura, Luis Francisco Linares Ferrando, Eugenio de Miguel Mendieta, Santiago Muñoz Fernández, Jose Luis Rosales-Alexander, Pedro Zarco Montejo, Mercedes Guerra Rodríguez & Victoria Navarro Compán. (2018) Recommendations by the Spanish Society of Rheumatology on the Use of Biological Therapies in Axial Spondyloarthritis. Reumatología Clínica (English Edition) 14:6, pages 320-333.
Crossref
Crossref
Jordi Gratacós, Petra Díaz del Campo Fontecha, Cristina Fernández-Carballido, Xavier Juanola Roura, Luis Francisco Linares Ferrando, Eugenio de Miguel Mendieta, Santiago Muñoz Fernández, Jose Luis Rosales-Alexander, Pedro Zarco Montejo, Mercedes Guerra Rodríguez & Victoria Navarro Compán. (2018) Recomendaciones de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en espondiloartritis axial. Reumatología Clínica 14:6, pages 320-333.
Crossref
Crossref
Gang Li, Chang-an Lv, Li Tian, Lian-jin Jin & Wei Zhao. (2018) A retrospective study of alendronate for the treatment of ankylosing spondylitis. Medicine 97:20, pages e10738.
Crossref
Crossref
Alireza Rezaiemanesh, Mohsen Abdolmaleki, Kamal Abdolmohammadi, Hamideh Aghaei, Fatemeh Dadgar Pakdel, Yousef Fatahi, Narjes Soleimanifar, Mahdi Zavvar & Mohammad Hossein Nicknam. (2018) Immune cells involved in the pathogenesis of ankylosing spondylitis. Biomedicine & Pharmacotherapy 100, pages 198-204.
Crossref
Crossref
Carole Bougault, Alaeddine El Jamal, Anne Briolay, Saida Mebarek, Marie-Astrid Boutet, Thomas Garraud, Benoit Le Goff, Fréderic Blanchard, David Magne & Leyre Brizuela. (2017) Involvement of sphingosine kinase/sphingosine 1-phosphate metabolic pathway in spondyloarthritis. Bone 103, pages 150-158.
Crossref
Crossref
James C.‐C. Wei, Dominique Baeten, Joachim Sieper, Atul Deodhar, Vaishali Bhosekar, Ruvie Martin & Brian Porter. (2017) Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52‐week pooled results from two phase 3 studies. International Journal of Rheumatic Diseases 20:5, pages 589-596.
Crossref
Crossref
Peter P. Cheung. (2017) Anti-IL17A in Axial Spondyloarthritis?Where Are We At?. Frontiers in Medicine 4.
Crossref
Crossref
Charles J. Malemud. 2017. Matrix Metalloproteinases and Tissue Remodeling in Health and Disease: Target Tissues and Therapy. Matrix Metalloproteinases and Tissue Remodeling in Health and Disease: Target Tissues and Therapy
305
325
.